Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement

The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib‐resistant patients, as may provide much longer ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Español, Ignacio, Romera, Marta, Gutiérrez‐Meca, María Dolores, García, Maria del Carmen, Tejedor, Aurelia, Martínez, Antonio, Ibáñez, Jerónima, De Arriba, Felipe, Minguela, Alfredo, Iturbe, Teodoro, López, Maria Dolores
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538069/
https://www.ncbi.nlm.nih.gov/pubmed/28781837
http://dx.doi.org/10.1002/ccr3.1015
Descripción
Sumario:The dismal outcome of pleuropericardial extramedullary multiple myeloma (EMM) reflects both the selection of resistant disease and absence of useful drugs. Carfilzomib and dexamethasone should be explored in advanced EMM patients, even for bortezomib‐resistant patients, as may provide much longer overall survival than previously reported treatments.

Ejemplares similares